Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
What have we learned from the COVID-19 pandemic, and what’s the future of HIV vaccine research? Find out this #HVAD2022.
HIV mutates rapidly, enabling the virus to evade the common, narrowly targeted antibodies produced by most people with HIV.
These dates represent milestones in the HIV epidemic. Visit poz.com/aidsiseveryday to learn more about the history of HIV/AIDS.
The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.
Understand what matters most about clinical trial endpoints for both advocates and researchers.
The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.
An expanded HIV Vaccine Trials Network Faith Initiative aims to reach Black, Latino and Indigenous communities of faith. [VIDEO]
An AVAC report also notes that most research and development of HIV prevention is funded almost entirely by one type of investor.
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.
New vaccine approach triggers neutralizing antibody production and T-cell responses and lowers risk of infection.
An experimental vaccine regimen did not protect young women from acquiring HIV in a large study in sub-Saharan Africa.
A study of HIV vaccines that use the same messenger RNA (mRNA) approach as highly effective COVID-19 vaccines has been launched.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
None of the available coronavirus vaccines have been linked to increased risk of HIV acquisition or disease progression.
More HIV prevention misinformation is coming from the right.
The Georgia governor erroneously claimed that Americans had refused to get a mandated AIDS vaccine. [VIDEO]
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.